Pharma sector
The article highlights a striking paradox: while India leads in the production of generic medicines, it continues to lag in developing new drugs, largely due to persistent regulatory delays.
It further emphasizes that without timely and decisive reforms, India could miss out on the AI-driven shift shaping high-value pharmaceutical innovation.
India stands as the world’s largest producer of generic medicines, yet it contributes very little to the creation of new drugs. A key constraint lies in its slow clinical trial approval process, where an overburdened regulatory system can take years to authorize trials that countries like China approve within days. As artificial intelligence rapidly shortens drug development cycles from years to mere months, this delay is narrowing India’s opportunity to emerge as a leader in next-generation pharmaceuticals. To stay competitive, India must urgently overhaul its clinical trial framework and strengthen its wider pharmaceutical ecosystem—otherwise, it risks remaining confined to low-margin generics in a future dominated by high-value, AI-powered drug innovation.
What Are the Major Recent Developments Shaping India’s Pharmaceutical Sector?
India’s pharmaceutical sector is undergoing a profound transformation, marked by a shift from volume-driven generic production to a more integrated, innovation-led ecosystem. One of the most significant changes is the country’s push toward upstream self-reliance. Long dependent on single-source imports—particularly for Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs)—India is now actively reducing this vulnerability. Through targeted policy measures, especially the Production Linked Incentive (PLI) scheme for bulk drugs, the country is transitioning from a “formulator-only” model to a vertically integrated manufacturing hub. By December 2025, the scheme had surpassed expectations, attracting ₹4,814 crore in investments against the committed ₹4,329 crore. This has led to the creation of 56,800 metric tonnes per annum capacity for critical APIs and KSMs, generating ₹2,720 crore in sales, including ₹528 crore in exports.
At the same time, India is making notable strides in pharmaceutical innovation. A landmark achievement is the development of Nafithromycin, the first antibiotic to be conceptualized and clinically validated within the country. This breakthrough signals India’s emergence as not just a generic drug manufacturer but also an innovator capable of addressing global challenges such as antimicrobial resistance (AMR). It demonstrates the growing capability of Indian research and development (R&D) to produce first-in-class molecules for critical health conditions.
Another defining trend is the sector’s transition to “Pharma 4.0,” characterized by the integration of digital technologies and artificial intelligence (AI) into drug discovery and manufacturing. By leveraging “digital biology,” companies are significantly reducing the traditional 10-year drug development timeline while improving production precision. AI-driven pharmacovigilance systems and the use of “digital twins” for clinical trial simulations are becoming mainstream. Reflecting this momentum, India’s clinical trials market is projected to reach USD 2,954.1 million by 2033.
Infrastructure development is also playing a pivotal role. The government’s push for Mega Bulk Drug Parks and Medical Device Parks is aimed at decentralizing production and lowering costs through shared facilities such as effluent treatment and logistics systems. These “clusters of excellence” are particularly beneficial for MSMEs, allowing them to scale operations without incurring heavy infrastructure costs. Three bulk drug parks have already been approved in Andhra Pradesh, Gujarat, and Himachal Pradesh, with central financial assistance supporting the creation of common infrastructure.
Quality compliance has become another central focus area. In response to global scrutiny, India revised Schedule M under the Drugs and Cosmetics Rules in 2024, strengthening Good Manufacturing Practices (GMP) requirements across facilities. With over 2,000 WHO-GMP approved plants and the highest number of USFDA-compliant facilities outside the United States, India is reinforcing its global credibility. Compliance with international standards is no longer optional but essential for accessing regulated markets such as the US and EU.
Simultaneously, the industry is diversifying into high-value segments such as New Biological Entities (NBEs) and biosimilars. The domestic biosimilar market, valued at approximately ₹437 crore in 2024, is projected to grow to ₹1,649 crore by 2034 at a CAGR of 14.2%. Leading companies like Cipla and Biocon are leveraging the PRIP scheme to advance research in cutting-edge therapies, including CAR-T cells and mRNA-based treatments.
India is also making progress in high-end medical device manufacturing, aiming to reduce its 70–80% import dependence on advanced equipment like MRI and CT scanners. The ₹3,420 crore PLI scheme for medical devices has already operationalized 55 products across 22 projects by September 2025, generating ₹12,344 crore in sales, including ₹5,869 crore in exports.
Further strengthening this trajectory is the government’s “Biopharma SHAKTI” initiative announced in the Union Budget 2026–27. This program seeks to build a comprehensive ecosystem for biologics and biosimilars, targeting a 5% share of the global biopharmaceutical market. The expansion of NIPER institutions will also bolster research and talent development in this high-value segment.
Environmental sustainability is emerging as a key priority. Indian pharmaceutical companies are increasingly adopting green chemistry, renewable energy, and flow chemistry techniques to meet stringent Environmental, Social, and Governance (ESG) standards. These measures not only reduce waste but also ensure continued access to global markets where sustainability compliance is becoming mandatory.
Key Issues Associated with India’s Pharma Sector
Despite these advancements, several structural challenges persist. One of the most pressing concerns is the quality perception crisis. Repeated global alerts over contaminated products have damaged India’s reputation, highlighting inconsistencies in GMP compliance, particularly among MSMEs. Inspections by CDSCO and state regulators across 905 units revealed widespread non-compliance, resulting in 694 regulatory actions by December 2025.
Another major issue is the innovation deficit. While India dominates the global generics market, it lags in developing new chemical entities due to limited R&D investment. Compared to global firms, Indian companies invest significantly less in research, often focusing on incremental improvements rather than breakthrough innovations.
Supply chain vulnerability remains a concern as well. Despite policy efforts, India still imports around 65–70% of its API requirements from China, leaving the sector exposed to geopolitical risks and price fluctuations.
Regulatory complexity further adds to the burden. Multiple authorities, including CDSCO and the National Pharmaceutical Pricing Authority, create overlaps and delays. Additionally, price controls under the National List of Essential Medicines (NLEM) have led to a margin squeeze, discouraging investment in advanced technologies.
The sector also faces a talent gap, with a shortage of skilled professionals in areas like bioinformatics and computational chemistry. This limits India’s ability to compete in emerging fields such as cell and gene therapy.
Sustainability challenges and rising ESG requirements pose another hurdle, especially for MSMEs that lack resources to transition to green manufacturing. Moreover, the digital divide—characterized by fragmented data systems and cybersecurity risks—hampers the adoption of Pharma 4.0.
Finally, the transition to biosimilars presents its own challenges, including high development costs, complex regulatory pathways, and patent barriers.
Measures to Strengthen India’s Pharmaceutical Sector
To address these challenges, India must undertake comprehensive reforms. Regulatory harmonization through a single-window system could streamline approvals and reduce compliance burdens. A unified national regulatory authority would ensure consistent quality standards and faster market access.
Boosting R&D investment is equally critical. Introducing innovation bonds, viability gap funding, and tax incentives for intellectual property can encourage firms to invest in high-risk drug discovery. Strengthening collaboration between industry, academia, and clinicians will help bridge funding gaps.
Enhancing supply chain resilience through circular bio-manufacturing and backward integration into KSMs can reduce import dependency. Simultaneously, adopting AI-driven technologies and blockchain for traceability will improve efficiency and restore global trust.
Addressing the talent gap requires revamping education systems and creating industry-ready training programs. Encouraging global collaboration and attracting skilled professionals can further strengthen human capital.
Strategic diversification into niche areas such as orphan drugs and neglected tropical diseases can provide a competitive edge. Government-backed incentives and procurement guarantees can support innovation in these areas.
Finally, embracing ESG principles and transitioning to sustainable manufacturing practices will be essential for long-term competitiveness.
Conclusion:
India’s pharmaceutical sector stands at a pivotal juncture. While it has established itself as the “Pharmacy of the World,” the next phase of growth will depend on its ability to innovate, adapt, and compete in a rapidly evolving global landscape. Bridging regulatory gaps, strengthening R&D, and embracing AI-driven transformation will be crucial. By focusing on quality, sustainability, and high-value innovation, India has the potential to emerge as a global leader in next-generation pharmaceuticals.
Also read: India’s Demographic Shift: Unlocking the Power of a Young Nation
Do follow: India is the pharmacy of the world. But we are losing the drug development race